Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

Clinical Trial ID NCT00381797

PubWeight™ 6.34‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00381797

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol 2010 1.50
2 The rationale for targeted therapies in medulloblastoma. Neuro Oncol 2013 0.92
3 Targeted brain tumor treatment-current perspectives. Drug Target Insights 2007 0.83
4 Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. Br J Clin Pharmacol 2015 0.81
5 Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors. J Clin Oncol 2012 0.78
6 Immune-based therapeutics for pediatric cancer. Expert Opin Biol Ther 2010 0.78
7 Advances in paediatric cancer treatment. Transl Pediatr 2014 0.76
Next 100